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clarify whether a multimodality approach
could protect the patients against tumor
recurrence.
The main problem of designing ran-
domized trials with neoadjuvant treatment
for patients with N1 NSCLC is how to
obtain an accurate lymph node staging with
the available diagnostic tools. Whereas cer-
vical mediastinoscopy is highly sensitive
and specific to exclude N2 as well as N3
status, computed tomographic scan of the
chest does not allow detection of lymph
node metastases in the stations 10 to 14 in
most cases. The simultaneous combination
of positron emission tomography and com-
puted tomographic scan, as well as endo-
scopic ultrasonography, could afford fur-
ther information about N1 nodes but are
not yet considered for routine use. We
agree with Margaritora and coauthors that
is difficult to achieve the histologic or cy-
topathologic assessment of N1 disease and
that more invasive diagnostic procedures
(eg, video-assisted thoracoscopy or thora-
cotomy) are to be considered improper for
routine clinical staging. Therefore, phase
III studies on neoadjuvant chemotherapy or
chemoradiotherapy in early stage NSCLC
could actually be designed only by exclud-
ing patients with N2 and N3 disease and
enrolling patients with true N1 and true N0
disease together.
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Influence of chromosome 22q11.2
microdeletion on surgical outcome
after treatment of tetralogy of Fallot
with pulmonary atresia
To the Editor:
We read with interest the important article
by Cho and colleagues1 recently published
on the Journal. The article reported the
huge surgical series of patients affected by
pulmonary atresia with ventricular septal
defect (PA-VSD) treated at the Mayo
Clinic during the last 20 years. The analy-
sis of follow-up data and risk factors re-
lated to surgery was extremely accurate,
and the operative results were excellent.
However, we noticed that the authors did
not take into consideration the possible as-
sociation with a genetic syndrome among
the hypothetic risk factors for surgical mor-
tality or morbidity.
The high prevalence of genetic abnor-
malities among patients with PA-VSD,
particularly the chromosome 22q11.2 mi-
crodeletion (Di George or velocardiofacial
syndrome) is well described in the litera-
ture,2-7 including important contributions
from the Mayo Clinic.6,7 Chromosome
22q11.2 microdeletion (del22q) has been
reported in about 40% of patients with PA-
VSD,2 particularly those with major aorto-
pulmonary collateral arteries (MAPCAs)3
and complex loop morphology of the pul-
monary arteries.4,5 The del22q abnormality
has also been related to peculiar perioper-
ative problems after surgery for PA-VSD,
such as persistent airway hyperresponsive-
ness or increased prevalence of infectious
complications.6,7
Among the surgical series of 37 consec-
utive patients with PA-VSD and MAPCAs
surgically treated at our institution between
January 1994 and March 2002 (mean age
39  48 months, range 22 days–13 years,
62% of patients 2 years old or younger),
genetically diagnosed del22q (fluorescence
in situ hybridization test) was present in 15
cases (40%, 95% confidence interval [CI]
24%-56%). Its occurrence did not relate to
any peculiar anatomic phenotype with re-
spect to either pulmonary vascular supply
(mean number of MAPCAs 3.7  1.3 for
15 patients with del22q, vs 3  1.4 for 22
patients without del22q, P not significant,
mean pulmonary arteries/collateral arteries
lung segment perfusion ratio 1.5 1.5 vs 2
 1.9, P not significant) or prevalences of
right aortic arch (53% [n  8] among pa-
tients with del22q vs 36% [n  8] among
patients without del22q, P not significant)
and infundibular atresia (53% [n  8]
among patients with del22q vs 50% [n 
11] among patients without del22q, P not
significant).
Twenty-five patients underwent total
unifocalization8 associated with successful
either primary (n  18) or secondary (n 
2) VSD closure in 80% of cases (20/25,
95% CI 64%-96%). The other 12 received
an intermediate right ventricular outflow
tract reconstruction with eventual second-
stage unifocalization and repair in 11 cases,
accounting for an overall repairability rate
of the disease of 86% (31/36, 95% CI 74%-
98%).
Mortality included 5 in-hospital deaths
(15%, 95% CI 3%-27%), and 1 late death.
Survival at 7-year follow-up was 81%.
Two deaths occurred during the immediate
postoperative course in 2 patients with
del22q; pulmonary vascular disease was
the cause in 1 case and no apparent cause
was found at autopsy in the other. Postop-
erative hospital infections, including 2 fun-
gal pneumonias, 1 fungal endocarditis, and
1 Pseudomonas pneumonia, occurred in 4
patients with del22q. Fungal infections
were always related to a decreased CD4
lymphocyte count on peripheral blood sam-
ples and were responsible for 2 of 3 further
in-hospital deaths. The last in-hospital
death was that of a patient with del22q
whose VSD was left open because of air-
way bleeding. Late death finally occurred
in the case of a patient with del22q who
had sudden airway bleeding early after suc-
cessful second-stage closure of VSD. In
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summary, all 6 deaths were among the pa-
tients with del22q, either related or unre-
lated to their immunodeficiency. This asso-
ciation was statistically significant [6/15 vs
0/22, difference –0.4, 95% CI –0.65 to
–0.15, P  .002].
In our experience microdeletion of
chromosome 22q11.2 appears associated
with poor overall outcome after surgical
treatment of PA-VSD with MAPCAs. We
believe that such a peculiarity, not neces-
sarily related to special anatomic cardiac
features associated with the syndrome it-
self, should justify the use of a protocol for
preoperative assessment of immunologic
status of patients with del22q undergoing
surgery for PA-VSD with MAPCAs and
the administration of a perioperative anti-
fungal prophylaxis when necessitated by a
depressed immunologic condition.
Within the population of patients with
complex congenital heart lesions, the prev-
alence of genetic syndromes is relevant.9
Genetic syndromes may influence both
clinical outcome and surgical results of
treatment of congenital heart defects, both
because of peculiar anatomic cardiac fea-
tures and because of associated extracar-
diac abnormalities.9,10 This is the main rea-
son that the possible association with a
genetic syndrome should always be in-
cluded among hypothetic risk factors
within the analysis of postoperative out-
come of congenital heart defects.
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Caveat against the use of FEIBA in
combination with recombinant factor
VIIa
To the Editor:
We appreciate the recent report from Bui
and colleagues1 on a fatal thrombosis after
administration of activated prothrombin
complex concentrate (FEIBA) in a patient
previously treated with recombinant acti-
vated factor VII (rFVIIa) for massive
bleeding during extracorporeal membrane
oxygenation. The activation of the coagu-
lation system by FEIBA is a rare but
known adverse reaction.2 A fatal thrombo-
sis after treatment with activated factor
VIIa and FEIBA has been described previ-
ously.3
Despite this, the hemostatic treatment in
this patients raises some further questions.
As the authors stated, the extracorporeal
circulation (ECC) induces a disseminated
intravascular coagulation–like state. A se-
rum level of fibrin degradation products of
4 supports this theory and moreover indi-
cates some degree of hyperfibrinolysis. Un-
fortunately, no information about the use of
antifibrinolytic agents (aprotinin, tranex-
amic acid) in this patient were provided.
We hypothesize that the use of antifibrino-
lytic agents might have attenuated the pro-
coagulant condition in this patient.
Fibrinogen is extensively consumed in
disseminated intravascular coagulation–
like states.4 Because fibrinogen levels were
not given for this patient, we have to spec-
ulate that fibrinogen levels in this patient
were below the normal range because of
profuse bleeding and elevated consump-
tion, resulting in high levels of fibrin deg-
radation products aggravating the bleeding
condition. On the other hand, we can spec-
ulate that the substitution of 22 units of
fresh-frozen plasma and, in particular, 30
units of cryoprecipitates may also have re-
stored supernormal fibrinogen and factor
VIII:c levels, which in this patient may
have promoted a procoagulant potential
possibly associated with the risk of throm-
bosis after administration of FEIBA.
Under conditions of profuse bleeding in
association with a disseminated intravascu-
lar coagulation–like state, antithrombin ac-
tivity is important. Antithrombin activity is
decreased in ECC because of an elevated
consumption,5 and thus the inhibitory po-
tential of the plasmatic coagulation system
may not have been preserved in this patient
despite the substitution of 22 units of fresh-
frozen plasma. Unfortunately, no informa-
tion regarding antithrombin activity was
provided. It is hypothesized that the substi-
tution of antithrombin might have reconsti-
tuted the inhibitory potential of the plas-
matic coagulation system, attenuating the
procoagulant response to FEIBA.
Finally, we agree with the authors that
the prothrombotic potential of rFVIIa is
low, because this reflects our own observa-
tions.6 From in vitro results,7 we have to
assume that the prothrombotic potential of
FEIBA is higher. However, we disagree
with the authors’ conclusions on two
points. First, despite the high safety profile
of rFVIIa, the use of rFVIIa in cardiac and
transplantation surgery needs further inves-
tigation before its use can be recom-
mended, in particular for patients with pro-
thrombotic risk factors.8 Second, the
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